SM
SIOX

SG3 Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

SG3 Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-500
Closed -$1K – 1477
2021
Q4 		$1K Hold
500
– – ﹤0.01% 1008
2021
Q3 		$1K Buy
+500
New +$1.09K ﹤0.01% 949
2021
Q2 		– Sell
-22,500
Closed -$59K – 1440
2021
Q1 		$59K Sell
22,500
-34,000
-60% -$96.2K ﹤0.01% 1086
2020
Q4 		$157K Buy
+56,500
New +$165K ﹤0.01% 895

Other funds holding SIOX

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

SG3 Management's SIOX Position: Q4 2021 in Review

SG3 Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2021, closing a stake of 9,230 shares — an estimated $16.4K sold.

SG3 Management first reported a position in SIOX in Q4 2020 and held it in 3 quarters. The position peaked at $91K in Q1 2021. 48 funds tracked by Wall St. Rank hold SIOX as of Q4 2021.

  • SG3 Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • SG3 Management sold 9,230 Sio Gene Therapies Inc. Common Stock shares in Q4 2021, an estimated $16.4K.
  • SG3 Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • SG3 Management's Sio Gene Therapies Inc. Common Stock position peaked at $91K in Q1 2021.
  • 48 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.